Novartis moving thousands of jobs out of Switzerland

The pharmaceutical giant is restructuring to focus more on personalised medicines, a move that will consolidate more than 2,000 jobs.

Swiss multinational pharmaceutical company Novartis has announced plans to cut about 1,500 manufacturing jobs in Switzerland by 2022.

It is looking to leverage cheaper labour in countries such as Malaysia instead.

According to reports, Novartis is planning to streamline its global manufacturing and service operations.

If the plan pushes through, the pharmaceutical giant will also cut up to 700 business service positions in Switzerland, on top of the 1,500 manufacturing jobs that it is eliminating.

These jobs will be then moved to the Czech Republic, India, Ireland, Malaysia and Mexico.

The closure of a plant in England will also see the loss of another 500 jobs.

The changes are necessary to help the company shift focus toward personalized medicines and boost its bottom line, according to Novartis CEO Vas Narasimhan, who took on the role in February this year.

As such, the job cuts will be slightly mitigated by the creation of 450 jobs in Switzerland, in the areas of cell and gene therapy manufacturing.

Share this articles!

More from HRM Asia

Subscribe to Our Newsletter

Stay updated with the latest HR insights and events,
delivered right to your inbox.

Sponsorship Opportunity

Get in touch to find out more about sponsorship and exhibition opportunities.